Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
After finishing at $5.19 in the prior trading day, Abeona Therapeutics Inc (NASDAQ: ABEO) closed at $5.1, down -1.73%. In other words, the price has decreased by -$1.73 from its previous closing price. On the day, 1.22 million shares were traded. ABEO stock price reached its highest trading level at $5.19 during the session, while it also had its lowest trading level at $4.9846.
Ratios:
Our goal is to gain a better understanding of ABEO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 9.53 and its Current Ratio is at 9.74. In the meantime, Its Debt-to-Equity ratio is 0.14 whereas as Long-Term Debt/Eq ratio is at 0.09.
On March 05, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $16.
On July 03, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.H.C. Wainwright initiated its Buy rating on July 03, 2024, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 29 ’25 when Seshadri Vishwas sold 25,000 shares for $5.31 per share. The transaction valued at 132,740 led to the insider holds 1,164,818 shares of the business.
Seshadri Vishwas bought 25,000 shares of ABEO for $132,695 on Dec 29 ’25. On Nov 13 ’25, another insider, Alvino Mark, who serves as the Director of the company, sold 15,000 shares for $4.74 each. As a result, the insider received 71,168 and left with 62,252 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABEO now has a Market Capitalization of 276375936 and an Enterprise Value of 93365944. As of this moment, Abeona’s Price-to-Earnings (P/E) ratio for their current fiscal year is 4.38. For the stock, the TTM Price-to-Sale (P/S) ratio is 690.93 while its Price-to-Book (P/B) ratio in mrq is 1.56. Its current Enterprise Value per Revenue stands at 233.415 whereas that against EBITDA is -1.153.
Stock Price History:
The Beta on a monthly basis for ABEO is 1.17, which has changed by 0.019646406 over the last 52 weeks, in comparison to a change of 0.19226205 over the same period for the S&P500. Over the past 52 weeks, ABEO has reached a high of $7.54, while it has fallen to a 52-week low of $3.93. The 50-Day Moving Average of the stock is 4.05%, while the 200-Day Moving Average is calculated to be -9.89%.
Shares Statistics:
The stock has traded on average 1.72M shares per day over the past 3-months and 1058840 shares per day over the last 10 days, according to various share statistics. A total of 52.40M shares are outstanding, with a floating share count of 49.49M. Insiders hold about 8.68% of the company’s shares, while institutions hold 62.41% stake in the company. Shares short for ABEO as of 1767139200 were 13246847 with a Short Ratio of 7.70, compared to 1764288000 on 13812286. Therefore, it implies a Short% of Shares Outstanding of 13246847 and a Short% of Float of 26.06.
Earnings Estimates
The market rating of Abeona Therapeutics Inc (ABEO) is currently shaped by the ongoing analysis conducted by 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.05 and low estimates of -$0.15.
Analysts are recommending an EPS of between $1.33 and -$1.6 for the fiscal current year, implying an average EPS of -$0.14. EPS for the following year is -$0.07, with 3.0 analysts recommending between $0.2 and -$0.36.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $18.67M. There is a high estimate of $24.9M for the next quarter, whereas the lowest estimate is $9.6M. Based on 7 analysts’ estimates, the company’s revenue will be $112.09M in the next fiscal year. The high estimate is $140.3M and the low estimate is $79.84M.
